Glancy Prongay & Murray LLP Commences Investigation on Behalf of Momenta Pharmaceuticals, Inc. Investors

Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Momenta Pharmaceuticals, Inc. (“Momenta” or the “Company”) (NASDAQ: MNTA) investors concerning the Company and its officers’ possible violations of federal securities laws.

On February 17, 2017, Momenta revealed that a contracted Pfizer facility was in receipt of a warning letter from the U.S. Food and Drug Administration ("FDA"). Three days later, analysts from Leerink Capital Partners LLC stated that the FDA letter is alarming due to the fact that manufacturing warning letters can take years to resolve, and that a lengthy delay could hurt Momenta's market opportunity for its Glatopa 40mg product candidate.

On this news, Momenta's share price has fallen as much as $4.30, or 22.63%, during intraday trading on February 21, 2017.

If you purchased Momenta securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170224005114/en/